514 related articles for article (PubMed ID: 25684767)
1. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
3. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
4. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
Grom AA; Ilowite NT; Pascual V; Brunner HI; Martini A; Lovell D; Ruperto N; ; Leon K; Lheritier K; Abrams K
Arthritis Rheumatol; 2016 Jan; 68(1):218-28. PubMed ID: 26314396
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
Yokota S; Itoh Y; Morio T; Origasa H; Sumitomo N; Tomobe M; Tanaka K; Minota S
Ann Rheum Dis; 2016 Sep; 75(9):1654-60. PubMed ID: 26644233
[TBL] [Abstract][Full Text] [Related]
6. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients.
Minoia F; Tibaldi J; Muratore V; Gallizzi R; Bracaglia C; Arduini A; Comak E; Vougiouka O; Trauzeddel R; Filocamo G; Mastrangelo A; Micalizzi C; Kasapcopur O; Unsal E; Kitoh T; Tsitsami E; Kostik M; Schmid JP; Prader S; Laube G; Maritsi D; Jelusic M; Shenoi S; Vastert S; Ardissino G; Cron RQ; Ravelli A;
J Pediatr; 2021 Aug; 235():196-202. PubMed ID: 33836183
[TBL] [Abstract][Full Text] [Related]
8. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.
Wu J; Sun L; Tang X; Zheng Q; Guo L; Xu L; Li Y; Lu M
Mod Rheumatol; 2022 Oct; 32(6):1114-1121. PubMed ID: 34971386
[TBL] [Abstract][Full Text] [Related]
9. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
[TBL] [Abstract][Full Text] [Related]
10. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
11. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
12. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Machado SH; Xavier RM
Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
[TBL] [Abstract][Full Text] [Related]
14. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
[TBL] [Abstract][Full Text] [Related]
16. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
[TBL] [Abstract][Full Text] [Related]
17. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
Miyamae T; Yokoya S; Yamanaka H; Yokota S
Mod Rheumatol; 2014 Jul; 24(4):567-71. PubMed ID: 24252004
[TBL] [Abstract][Full Text] [Related]
18. Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2.
Tasaki Y; Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Wada T; Yachie A
Cytokine; 2016 Apr; 80():1-6. PubMed ID: 26908294
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]